CHIESI FARMACEUTICI S.P.A.

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1935-01-01

Employees: -

Market Cap: -

Website: http://www.chiesigroup.com

Clinical Trials

A Study in Preterm Neonates With Respiratory Distress Syndrome (RDS) Comparing CUROSURF® Administration Through Less Invasive Surfactant Administration (LISA) and Conventional Administration

Phase 3

Terminated

Conditions: Respiratory Distress Syndrome (RDS)

Interventions: Combination Product: LISA combination product (Curosurf+catheter CHF6440)
Drug: Curosurf through conventional administration (endotracheal tube)

First Posted Date: 2016-05-13

Last Posted Date: 2023-11-07

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 33

Registration Number: NCT02772081

Locations: 🇺🇸
Chiesi Clinical Trial Site 84002, Los Angeles, California, United States
🇺🇸
Chiesi Clinical Trial Site 84012, Camden, New Jersey, United States
🇺🇸
Chiesi Clinical Trial Site 84024, Manhasset, New York, United States

and more 23 locations

Cangrelor Neonatal PK/PD and Safety Study

Phase 1

Completed

Conditions: Partial Obstruction of Systemic to Pulmonary Artery Shunt
Complete Obstruction of Systemic to Pulmonary Artery Shunt

Interventions: Drug: Cangrelor

First Posted Date: 2016-05-06

Last Posted Date: 2023-02-15

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 22

Registration Number: NCT02765633

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States

Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and the Lung Availability of CHF 5993 in Healthy Volunteers

Phase 1

Completed

Conditions: COPD

Interventions: Drug: CHF 5993 100/6/12,5 pMDI with Valved Holding Chamber
Drug: CHF 5993 100/6/12,5 DPI Test 2
Drug: CHF 5993 100/6/12,5 pMDI
Drug: CHF 5993 100/6/12,5 pMDI replicate
Drug: CHF 5993 100/6/12,5 DPI Test 1

First Posted Date: 2016-04-19

Last Posted Date: 2021-07-02

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 50

Registration Number: NCT02743013

Locations: 🇧🇪
SGS CPU Antwerpen, Antwerpen, Belgium

Study to Evaluate Efficacy/Safety of 4 Doses of CHF5259 Via Dry Powder Inhaler (DPI) in Patients With COPD

Phase 2

Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: CHF5259 or Placebo administration

First Posted Date: 2016-02-11

Last Posted Date: 2020-07-31

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 262

Registration Number: NCT02680197

Locations: 🇭🇺
Clinical Trial Site 348-005, Komarom, Hungary
🇭🇺
Clinical Trial Site 348-002, Létavértes, Hungary
🇭🇺
Clinical Trail Site 348-009, Seregélyes, Hungary

and more 27 locations

TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: CHF 5993 100/6/12.5 µg
Drug: CHF 1535 100/6 µg

First Posted Date: 2016-02-08

Last Posted Date: 2021-04-08

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 1153

Registration Number: NCT02676076

Locations: 🇩🇪
Chiesi Clinical Trial Site 276814, Rostock, Germany

TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER)

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: CHF 1535 200/6 µg
Drug: CHF 5993 200/6/12.5 µg
Drug: CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg

First Posted Date: 2016-02-08

Last Posted Date: 2021-04-08

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 1433

Registration Number: NCT02676089

Locations: 🇦🇷
Chiesi Clinical Trial Site 432702, Ciudad Autónoma de Buenos Aires, Argentina
🇪🇸
Chiesi Clinical Trial Site 724703, Badajoz, Spain
🇦🇷
Chiesi Clinical Trial Site 432705, Mar Del Plata, Argentina

and more 241 locations

2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD Patients

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: CHF 5993 + Ultibro matched placebo
Drug: Ultibro + CHF 5993 matched placebo
Procedure: Central spirometry
Other: COPD assessment test
Procedure: Local laboratory Assessments
Other: Saint George's Respiratory Questionnaire
Other: EXACT-pro questionnaire

First Posted Date: 2015-10-20

Last Posted Date: 2021-10-29

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 1532

Registration Number: NCT02579850

Locations: 🇮🇹
Chiesi Farmaceutici S.p.A., Parma, Italy

Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma

Phase 2

Completed

Conditions: Severe Eosinophilic Asthma

Interventions: Drug: Placebo
Drug: OC000459

First Posted Date: 2015-09-25

Last Posted Date: 2019-08-29

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 40

Registration Number: NCT02560610

Locations: 🇬🇧
University of Oxford, Oxford, Oxfordshire, United Kingdom

Pharmacokinetic Study of ENVARSUS in Adult De-novo Kidney Transplant Patients

Phase 4

Completed

Conditions: Organ or Tissue Transplant; Complications

Interventions: Drug: ADVAGRAF®
Drug: ENVARSUS®

First Posted Date: 2015-07-16

Last Posted Date: 2020-07-31

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 75

Registration Number: NCT02500212

Locations: 🇫🇷
Clinique de Nephrologie CHU Grenoble, Grenoble, France
🇫🇷
Nephrology department CHU de Saint-Etienne Hospital Nord, Saint Etienne, France
🇫🇷
Service de Nephrologie, Montpellier, France

and more 4 locations

Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: FlF/VI + Tiotropium
Drug: BDP/FF/GB

First Posted Date: 2015-06-10

Last Posted Date: 2021-10-29

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 1479

Registration Number: NCT02467452

Locations: 🇭🇺
Erzsebet Gondozohaz, Godollo, Hungary

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy